Order Article Reprints

Perrone E, Giordano A, Calcagni ML, Leccisotti L, Moretti R, Eismant A, Ghai K, Parkar T, Mishra A, Heidenreich A, et al. Long-Term Safety and Survival Outcomes of [²²⁵Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [²²⁵Ac]Ac-/[¹⁷⁷Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. Cancers. 2025; 17(3):405. https://doi.org/10.3390/cancers17030405

Perrone, Elisabetta, Alessandro Giordano, Maria Lucia Calcagni, Lucia Leccisotti, Roberto Moretti, Aleksandr Eismant, Kriti Ghai, Tanay Parkar, Aditi Mishra, Axel Heidenreich, and et al. 2025. "Long-Term Safety and Survival Outcomes of [²²⁵Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [²²⁵Ac]Ac-/[¹⁷⁷Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer" Cancers 17, no. 3: 405. https://doi.org/10.3390/cancers17030405

Perrone, E., Giordano, A., Calcagni, M. L., Leccisotti, L., Moretti, R., Eismant, A., Ghai, K., Parkar, T., Mishra, A., Heidenreich, A., Wirtz, R. M., Müller, J., Greifenstein, L., & Baum, R. P. (2025). Long-Term Safety and Survival Outcomes of [²²⁵Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [²²⁵Ac]Ac-/[¹⁷⁷Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. Cancers, 17(3), 405. https://doi.org/10.3390/cancers17030405